Researchers identified seven dimensions of hyperarousal and developed the Transdiagnostic Hyperarousal Dimensions Questionnaire (THDQ), a tool designed to standardize assessment across mental health disorders. The framework could support more precise diagnosis and treatment as mental health demand rises in Mexico, influencing healthcare providers, digital health platforms, and employers expanding workplace wellness programs.
A 2026 study in eClinicalMedicine has identified seven distinct dimensions of hyperarousal, a core symptom shared across multiple mental health disorders, and introduced a concise tool—the Transdiagnostic Hyperarousal Dimensions Questionnaire (THDQ)—to assess them. Researchers say the tool could streamline diagnosis, support personalized treatment, and enable large-scale studies using existing data like the UK Biobank.
Understanding Hyperarousal
Hyperarousal refers to a heightened state of physiological and emotional activation, in which the body’s “fight-or-flight” response remains active beyond immediate threats. Symptoms can include hypervigilance, exaggerated startle responses, sleep difficulties, irritability, palpitations, and sensory sensitivity. While commonly linked to conditions such as post-traumatic stress disorder (PTSD), insomnia, and anxiety, hyperarousal has historically been inconsistently defined and measured.
The eClinicalMedicine study analyzed 221 items across 18 existing questionnaires and identified seven core dimensions: Anxious, Somatic, Sensitive, Sleep-related, Irritable, Vigilant, and Sudomotor (sweating and facial flushing). These dimensions collectively explained over 50% of the variance in participant responses.
“By distinguishing these dimensions, clinicians can better understand the specific profiles that drive individual disorders,” said the study authors. For example, generalized anxiety disorder primarily aligns with the Anxious dimension, whereas insomnia corresponds to Sleep-related hyperarousal. PTSD showed the strongest associations with Vigilant and Sudomotor dimensions, illustrating how complex and overlapping hyperarousal profiles can be.
Development of the THDQ
To facilitate assessment, researchers developed the 27-item Transdiagnostic Hyperarousal Dimensions Questionnaire (THDQ) and validated it with a sample of 592 participants. The tool showed strong reliability (Cronbach’s alpha = 0.90) and maintained consistency even a year after initial testing.
Additionally, the study identified 22 items already included in the UK Biobank, which can reliably estimate Anxious, Irritable, and Sleep-related dimensions. This integration enables large-scale research linking hyperarousal traits to genetic and neuroimaging data, expanding the potential for precision medicine approaches.
Clinical and Public Health Implications
Distinguishing hyperarousal dimensions could inform personalized treatment strategies. For example, a patient with insomnia who also presents elevated Vigilant and Sudomotor scores may require interventions targeting underlying post-traumatic stress rather than standard sleep therapies.
Hyperarousal is increasingly recognized as a contributor to broader mental and physical health issues. Chronic sleep disruption, which overlaps with Sleep-related hyperarousal, has been linked to accelerated cognitive decline and higher dementia risk.
A 2025 study in Neurology found that adults with persistent insomnia had a 40% increased risk of dementia and showed evidence of accelerated brain aging. Experts highlight that insomnia remains under-recognized and undertreated, reinforcing the need for integrated screening and intervention.
Low-cost, complementary approaches such as journaling have shown modest benefits in alleviating anxiety, depression, and PTSD symptoms. Systematic reviews indicate that structured expressive writing and gratitude journaling can improve emotional regulation, self-compassion, and cognitive recall. Longer interventions, particularly those over 30 days, were most effective, suggesting that integrating behavioral strategies with traditional clinical care could reinforce treatment outcomes.
Broader Context: Post-Pandemic Mental Health
In Mexico, five years after the COVID-19 pandemic, mental health challenges remain pronounced. Studies report that 20% of the population experiences depression, with young adults and middle-aged individuals most affected. Anxiety impacts over half of patients seeking treatment; burnout, PTSD, and substance use continue to rise. Economic pressures and limited vacation time exacerbate stress, contributing to chronic sleep deficits and workplace productivity losses.
Companies and health institutions are increasingly adopting emotional wellness programs, mental health days, and telemedicine solutions to address these gaps. Experts note that AI-driven mental health platforms may complement human providers, expanding access despite workforce shortages.